Table 2.
Prospective performance of the OLM CandID real-time PCR when testing serum with DNA extracted using the Roche MagNA Pure 96.
| Population (n = 103) | Parameter | ||||||
|---|---|---|---|---|---|---|---|
| Se (%, 95% CI) |
Sp (%, 95% CI) |
PPV (%, 95% CI) |
NPV (%, 95% CI) |
LR +tive | LR -tive | DOR | |
| Candidemia (4) vs. no IC (79) | 100 (51–100) | 82 (72–89) | 22 (9–45) | 100 (94–100) | 5.6 | <0.001 | >4571 |
| Probable/chronic IC (2) vs. no IC (79) | 100 (34–100) | 82 (72–89) | 13 (4–36) | 100 (94–100) | 5.6 | <0.001 | >4571 |
| Combined candidemia/prob/chronic IC (6) vs. no IC (79) | 100 (61–100) | 82 (72–89) | 30 (15–52) | 100 (94–100) | 5.6 | <0.001 | >4571 |
| Possible IC (18) vs. no IC (79) | 83 (61–94) | 82 (72–89) | 52 (34–69) | 96 (88–98) | 4.7 | 0.20 | 22.9 |
| All IC (24) vs. no IC (79) | 88 (69–96) | 82 (72–89) | 60 (44–74) | 96 (88–98) | 4.9 | 0.15 | 32.5 |
Only one case of candidemia was PCR positive in duplicate and/or PCR positive on multiple samples. Only one case of probable/chronic IC was PCR positive in duplicate and/or PCR positive on multiple samples. Thirteen cases of possible IC were PCR positive in duplicate and/or PCR positive on multiple samples. Only four control patients were PCR positive in duplicate. Key: Se, sensitivity; Sp, specificity; PPV, positive predictive value; NPV, negative predictive value; LR + tive, positive likelihood ratio; LR-tive, negative likelihood ratio; DOR, diagnostic odds ratio.